Standardization study for clinical diagnosis and treatment of Hashimoto thyroiditis treated by the Shu-Gan Qing-Huo Chinese medicine

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017737

Enrollment

Unknown

Registered

2018-08-11

Start date

2019-01-01

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hashimoto's thyroiditis

Interventions

Experimental group:Conventional treatment same as control group plus Shu-Gan Qing-Huo Chinese medicine

Control group:hyperthyroidism and hypothyroidism will be given methimazole tablets 10 mg/d (trade name: Saizhi. Germany Merck, batch number 116476), levothyroxine tablets 25-50 µg/d (trade name: Eucal

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. meet the diagnostic criteria of Hashimoto's thyroiditis and serum TGAb, TPOAb indicators within the measurable range; 2. patients with a clear sense of consciousness, voluntarily participate in the study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. thyroid enlargement of the adjacent organs or thyroid heart disease; 2. thyroid enlargement with exophthalmos, TGAb (+), and TPOAb titer slightly increased and diagnosed as other thyroid diseases; 3. serious heart, liver, kidney Such as organ complications and blood system diseases; 4. pregnant or lactating women; 5. allergic constitution; 6. poor compliance, withdrawal and incomplete data, but the adverse reactions occurred in the statistics.

Design outcomes

Primary

Measure	Time frame
TPOAb;TPOAb;	—

Countries

China

Contacts

Public ContactZhang Yi

Shanghai Traditional Chinese Medicine Hospital

1046@szy.sh.cn+86 18116070306

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026